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Mycobacterium avium-M. intracellulare complex infection is a serious acquired immunodeficiency syndrome
(AIDS)-related opportunistic infection which is diagnosed in
more than 50% of AIDS patients (2, 19, 23, 36, 40). The
organism multiplies primarily in resident macrophages of the
lungs, spleen, liver, and lymph nodes of infected individuals
(19, 23, 36, 39, 40). Anti-M. avium-M. intracellulare complex therapy with the available antimycobacterial drugs
remains ineffective in both AIDS and non-AIDS patients (4,
20, 22, 38). Many drugs that have high in vitro activity
against the M. avium-M. intracellulare complex (21, 37)
have limited efficacy in vivo (28, 38; P. R. J. Gangadharam,
V. K. Perumal, N. R. Podapati, K. Parikh, and M. D.
Iseman, 3rd Int. Conf. AIDS, abstr. no. THP147, p. 188,
1987). Inability of the drugs to achieve bactericidal levels at
the sites of infection without producing unacceptable toxicity limits the efficacy of current anti-M. avium-M. intracellulare complex therapy. Thus, targeting of drugs to sites of
M. avium-M. intracellulare complex infection is imperative
if in vivo efficacy is to be enhanced.
In contrast to several drugs with limited in vivo activity in
animal models and in patients, amikacin has been shown to
be effective against the M. avium-M. intracellulare complex
both in vitro and in vivo. Amikacin has anti-M. avium-M.
intracellulare complex activity in vitro at concentrations
*

achievable in serum (37) and under simulated in vivo conditions in which the drug concentration is decreased over time
(15). In the acute-infection model of the disease in beige mice
(13), amikacin has been demonstrated to have high activity
by itself or in combination with clofazimine or rifabutine or
both (17). However, to be effective in vivo, amikacin has to
be administered intramuscularly (i.m.) at high doses (50 mg/
kg) daily for prolonged periods (6 to 8 weeks in the beigemouse model). It is therefore necessary to develop methods
to reduce the amount of the drug given and decrease the
number of administrations without decreasing the in vivo
activity. In this report, we describe the use of liposomes for
therapy of M. avium-M. intracellulare complex infections in
mice, both as a means to target antibiotics to infected organs
and as a method to decrease the total dose of the drug that
must be administered.
Liposomes are phospholipid bilayer vesicles that can
encapsulate a variety of drugs and macromolecules. They
are avidly phagocytosed by macrophages both in vivo and in
vitro and are naturally targeted to the major organs involved
in disseminated infection with the M. avium-M. intracellulare complex (9, 31-33). Thus, liposomes are potentially
ideal vehicles for directing drugs to sites of M. avium-M.
intracellulare infection. Administration of liposome-encapsulated antibiotics and antiviral agents has resulted in enhanced efficacy against a number of infections localized in
the reticuloendothelial system, including Leishmania dono-
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We examined the therapeutic effects of free and liposome-encapsulated amikacin on Mycobacterium
avium-M. intracellulare complex infection by using the beige-mouse model of the disease. In the first series of
studies, intravenous administration of four weekly doses of 5 mg of amikacin per kg encapsulated in large
(approximately 0.4-pm diameter), unilamellar liposomes arrested the growth of M. avium-M. intraceUulare
complex organisms in the liver, as measured by CFU counts. M. avium-M. intracelulare complex levels in
untreated animals and in those treated with the same dose of free amikacin increased by several orders of
magnitude over 8 weeks. Liposome-encapsulated amikacin was also effective against M. avium-M. intracellulare
complex organisms in the spleen and kidneys, reducing the CFU counts by about 1,000-fold compared with
those of both untreated controls and free-drug-treated mice. In the lungs, a slight reduction in CFU was
observed in the liposome-encapsulated-amikacin-treated group, but only at the 8-week point. Neither free nor
liposome-encapsulated amikacin reduced the colony counts in the lymph nodes compared with those of control
animals. Reductions in CFU in ail organs greater than those caused by the liposome preparation could be
achieved by intramuscular administration of free amikacin, but only at a 10-fold-higher dose given 6 days a
week for 8 weeks. In the second series of studies, we investigated the effects of (i) doubling the dose of
liposome-encapsulated amikacin and (ii) increasing the size of the liposomes and prolonging the treatment to
five injections. Administration of 10 mg of amikacin per kg in liposomes 2 to 3 ,um in diameter was more
effective in the liver than 5 or 10 mg of amikacin per kg in liposomes 0.2 ,um in diameter. A slight reduction
in the CFU levels in the lungs was observed with the higher dose, irrespective of liposome size. Our results
indicate that liposome-based delivery of amikacin enhances its anti-M. avium-M. intracellulare complex
activity, particularly in the liver, spleen, and kidney, and may therefore improve the therapy of this disease.

ANTIMYCOBACTERIAL EFFECT OF AMIKACIN IN LIPOSOMES

vani, Listeria monocytogenes, Candida albicans, and Rift
Valley fever virus (1, 3, 25, 27). In this study, we compared
the efficacies of free and liposome-encapsulated amikacin on
the multiplication of M. avium-M. intracellulare complex
organisms in beige mice.
MATERIALS AND METHODS
Drugs and reagents. Amikacin sulfate was obtained from
Sigma Chemical Co. (St. Louis, Mo.). Phosphatidylglycerol
and phosphatidylcholine, both prepared from egg yolk, were
obtained from Avanti Polar Lipids (Birmingham, Ala.).
Cholesterol was purchased from Behring Diagnostics and
recrystallized twice from methanol. NaCl was from Mallinckrodt Inc. (St. Louis, Mo.), KCI was from Fisher Scientific Co. (Pittsburgh, Pa.), and HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) and glycine were from
Sigma.
Strain of M. avium-M. intracellulare complex and infection
of animals. A single-cell suspension of a predominantly
(>95%) transparent colony type of the M. avium-M. intracellulare complex (strain 101; serotype 1) was used for the
experiments. The strain was originally isolated from the
blood of a patient with AIDS in California and was obtained
from Clark Inderlied. The organisms were maintained by
repeated passages through beige mice to retain their virulence (14, 18). Each animal received approximately 106 to
107 viable units of the organism by intravenous (i.v.) injection. Five- to seven-week-old male beige (C57BL/6/bg/bgJ)
mice were used for the experiments. The animals were kept
five to a cage in a biohazard room. Food and water were
given ad libitum.
Preparation of liposomes. Amikacin was encapsulated in
liposomes composed of phosphatidylglycerol-phosphatidylcholine-cholesterol (1: 1:1 molar ratio) by reverse-phase
evaporation followed by extrusion through polycarbonate
membranes (10, 34). A sterile 50-mg/ml solution of amikacin
in 10 mM KCl-5 mM glycine, pH 9.6, adjusted to an
osmolality of 300 mosM with NaCI, was added to a solution
of the lipids in diethyl ether (50 ,umol of lipid in 2 ml) at a 1:3
ratio, and the mixture was sonicated under argon for 5 min.
The resulting emulsion was placed in a rotary evaporator and
evaporated under controlled vacuum as described previously (10). To eliminate any residual ether, the suspension
was supplemented with 1.32 ml of the amikacin solution and
placed in the evaporator for an additional 20 min. The
liposomes were then extruded through polycarbonate membranes with a 0.2-,um pore diameter (Nuclepore Corp.,
Pleasanton, Calif.) under argon pressure. Unencapsulated
amikacin was eliminated by chromatographing the liposome
suspension on sterilized Sephadex G-75 with 140 mM NaCl10 mM KCl-10 mM glycine, pH 9.6, as the elution buffer. To
ensure the sterility of the liposome suspension, the latter was
filtered through a 0.22-,um (pore size) filter (Schleicher &
Schuell, Inc., Keene, N.H.). The size distribution of the
liposomes was ascertained in an NP-4 dynamic light-scattering instrument (Coulter Electronics, Inc., Hialeah, Fla.).
The mean diameter of the vesicles was in the range of 400
nm, with a standard deviation of 140 nm. In the second series
of experiments, large, multilamellar vesicles were prepared
by drying the lipid from a chloroform solution onto the sides
of a glass tube as a thin film and hydrating the lipid with the
amikacin solution by slow rotation for several hours. The
unencapsulated material was separated from the liposomes
by repeated centrifugation and washing with elution buffer.
The size distribution of these vesicles was in the range of 2

1405

to 3 p.m, as estimated by a Coulter Channelyzer with latex

particles

as standards.
The amount of encapsulated amikacin was determined by
an enzyme-linked immunosorbent assay after the liposomes
were lysed with 0.5% Triton X-100 by using an aca discrete
clinical analyzer (Du Pont Co., Wilmington, Del.). The assay
is based on the activity of glucose-6-phosphate dehydrogenase conjugated to amikacin. The enzyme is inhibited when
the conjugate is bound to anti-amikacin antibody. The
amount of bound conjugate is determined by the concentration of free amikacin, which competes for the antibody.
Phospholipid concentrations were determined by phosphate
analysis (5). Control liposomes containing buffer only, without amikacin, were prepared with 140 mM NaCI-10 mM
KCI-5 mM glycine, pH 9.6, as the aqueous medium.
Administration of drugs. In the first series of experiments,
free or liposome-encapsulated amikacin was administered to
mice i.v. via a caudal vein at a dose of 100 ,ug per mouse per
week (5 mg/kg once a week). Treatment was started 1 day
after infection and was continued for 3 weeks (a total of four
injections). In addition, one group of animals received a
daily dose of 1 mg per mouse (50 mg/kg daily) i.m. 6 days a
week for the entire 8-week period of the experiment. Two
control groups were included, one receiving empty (bufferloaded) liposomes administered at the same lipid concentration as the amikacin-liposome group and the other receiving
buffer. In the second series of experiments, the same protocol was followed, except that two doses of liposome-encapsulated amikacin (5 and 10 mg/kg) were administered in five
weekly injections, and another group of mice was given 10
mg of amikacin per kg in large, multilamellar vesicles. Free
amikacin was given i.v. at a dose of 10 mg/kg. In these
experiments, the effect of i.m. amikacin was not investigated. Control groups were given buffer or buffer-loaded
liposomes at the same lipid concentration as the liposomes
used for the 10-mg/kg dose in unilamellar vesicles.
Assessment of results. Three randomly selected mice were
killed on day 1 following infection (base line) and at 2-week
intervals thereafter for up to 8 weeks. The CFU counts were
determined in the liver, spleen, lungs, kidneys, and pooled
lymph nodes (superficial inguinal, mesenteric, superficial
deep cervical, and renal), following homogenization and
plating on 7H11 agar medium.
Statistics. Standard randomization procedures were used
in selecting animals to be killed at scheduled intervals. To
avoid bias, the identity of the group of animals was concealed from the observer until the CFU counts were enumerated. Student's t test and analysis of variance were used
in individual experiments to analyze the data.

RESULTS
Effect of amikacin treatment on the progress of M. aviumM. intracellulare complex disease. The effect of treatment
with the free and liposome-encapsulated forms of amikacin
on the progress of M. avium-M. intracellulare complex
disease over a period of 8 weeks is discussed separately for
each tissue type.
(i) Liver. The progress of M. avium-M. intracellulare
complex infection in the liver over an 8-week period and the
effect of treatment are shown in Fig. 1. Administration (i.v.)
of four weekly low doses of amikacin (5 mg/kg) encapsulated
in liposomes prevented in vivo multiplication of the M.
avium-M. intracellulare complex. In contrast, the CFU
counts increased monotonically in control animals that received injections of buffer of liposomes containing buffer
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only (empty liposomes). The same dose of the free drug
given under the same conditions did not arrest the growth of
the organisms. At the 8-week point, CFU counts in the
liposome-encapsulated amikacin group were more than 3
orders of magnitude below those of the buffer or emptyliposome controls and the free-amikacin group. The effect of
liposome-encapsulated amikacin persisted for at least 5
weeks after the termination of treatment. Although amikacin
targeted to the liver via liposomes was effective in arresting
M. avium-M. intracellular complex growth, it did not reduce
the number of viable organisms.

Duration - Weeks
FIG. 2. Time course of M. avium-M. intracellulare complex
infection in the spleen and effect of amikacin therapy. The results
are given as mean log M. avium-M. intracellulare complex CFU per
milliliter of tissue. The symbols are defined in the legend to Fig. 1.

Previous studies (17) on the therapeutic effect of amikacin
have used i.m. administration of the drug at a daily dose of
50 mg/kg. We compared this i.m. dose of amikacin with the
i.v. dose under the same experimental conditions (Fig. 1).
Amikacin administered i.m. 6 days a week for the entire 8
weeks showed the greatest reduction in CFU counts (Table
1). However, at the 2-week point, the CFU counts were
significantly higher than those of the liposome-encapsulated
amikacin group (P < 0.0005), even though the total i.m. dose
of amikacin was 60-fold higher.
(ii) Spleen. Essentially similar results were obtained in the
spleen and the liver. Liposome-encapsulated amikacin was
more effective than the free drug given i.v. (Fig. 2). By 2
weeks, the CFU counts in animals treated with liposomal
amikacin were about 1.5 orders of magnitude lower than the
CFU in untreated animals and those that received the free

TABLE 1. Comparison of the reduction in CFU counts in beige mice treated with free or liposome-encapsulated
amikacin administered i.v. or amikacin given i.m.
Time and treatment

Total dose

Reduction of mean log CFU relative to control

(jig)

Liver

Spleen

Lungs

Kidneys

Lymph nodes

0
200
200
12,000

-0.07
1.37
-0.10
0.62

0.11
1.46
0.00
0.32

0.03
0.08
0.03
1.10

-0.10
1.11
-0.11
1.15

1.18
0.85
-0.44
1.16

0
400
400
24,000

-0.04
2.12
0.10
3.34

-0.02
1.56
-0.06

0.71
1.57
0.73
3.43

-0.29

1.77

0.05
0.21
-0.10
2.76

Amikacin-liposomes
Free amikacin
Amikacin i.m.

0
400
400
36,000

-0.20
2.97
1.36
5.12

-0.03
3.17
0.99
4.14

-0.15
0.66
0.80
4.71

-0.10
1.98
0.78
4.18

-0.32
0.71
0.08
4.78

8 Wk
Empty liposomes
Amikacin-liposomes
Free amikacin
Amikacin i.m.

0
400
400
48,000

0.10
3.45
0.26
5.23

0.25
2.95
0.28
4.23

-0.21
0.57
-0.22
4.59

1.16
3.14
0.86
6.01

0.24
0.24
0.54
4.54

2 Wk
Empty liposomes

Amikacin-liposomes
Free amikacin
Amikacin i.m.
4 Wk

Empty liposomes
Amikacin-liposomes
Free amikacin
Amikacin i.m.
6 Wk
Empty liposomes

0.13
-0.24
1.95

Downloaded from https://journals.asm.org/journal/aac on 23 July 2021 by 69.168.126.100.

FIG. 1. Progression of M. avium-M. intracellulare complex infection in the livers of beige mice (O) and effects of weekly
injections of free (a) or liposome-encapsulated (0) amikacin or
buffer-loaded liposomes (A). The data are presented as mean log
CFU counts of M. avium-M. intracellulare complex organisms per
milliliter of tissue. Amikacin was administered in four weekly i.v.
injections, starting 1 day after infection. The effects of i.m. injections of 50 mg of free amikacin per kg 6 days a week for 8 weeks are
also shown (0). Each point represents the mean of three animals.
The bars represent standard deviations. For points without a bar,
the standard deviation is within the magnitude of the symbol.
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FIG. 4. Effect of amikacin therapy on M. avium-M. intracellulare complex infection in the kidneys, shown as log CFU per
milliliter of tissue. The symbols are the same as in Fig. 1.

drug. At 8 weeks, i.e., 5 weeks after the end of treatment,
the CFU counts were approximately 3 orders of magnitude
lower

in

animals

liposome-encapsulated-amikacin-treated

than in controls or those receiving free amikacin i.v. The
CFU in the spleens of untreated or free-amikacin-treated
mice increased by

orders of magnitude in 8 weeks, whereas
animals the in-

in liposome-encapsulated-amikacin-treated

crease was only 2 orders of magnitude. It is of interest that
animals

treated

with

showed a considerable

liposome-encapsulated
reduction

amikacin

in CFU compared

with

controls at the 2-week point, at which time the daily i.m.
treatment with the high dose did not show any effect (P <
0.0005; Table 1 and Fig. 2). At 4 weeks, the CFU counts in
the two groups were similar, despite the 60-fold-higher dose
i.m. amik acin.

(iii) Lungs. CFU levels in lungs were not affected by i.v.
of free or liposome-encapsulated

administration

amikacin

over the 6-week period. At 8 weeks, the liposome-encapsu-

group, showed a reduction in CFU counts below the baseline (day 1) level after 4 weeks (P < 0.005).
Comparison of i.v. and i.m. doses. Table 1 summarizes the
changes in CFU counts in all of the tissues of M. avium-M.
intracellulare complex-infected beige mice treated with the
three amikacin regimens. For comparison, the total doses of
the drug administered are also included. A considerable
reduction in CFU counts compared with those of controls
was observed in the i.m. and liposome-encapsulated-amikacin treatment groups. At 2 weeks, the liposome group
showed a greater reduction than the i.m. group in both the
liver and the spleen. If the reduction in CFU counts is
expressed with respect to the unit dose of the drug administered, the group treated with liposome-encapsulated amikacin showed a remarkable efficiency of therapeutic response. For example, at 2 weeks, the reduction in CFU in
the spleen per unit dose of liposome-encapsulated amikacin
was 1,280-fold greater than in the i.m. amikacin group and
390-fold greater in the liver. At the 4-week point, these

lated-amikacin-treated group exhibited a slight reduction in
CFU counts compared with those of the untreated control

8

group (P < 0.025; Fig. 3). Administration of amikacin i.m. at
high doses did reduce the CFU counts below the base-line
(day

1)

starting

level,

at the

2-week point,

reaching

1.6

orders of magnitude below this level by week 6.
(iv) Kidneys. In the kidneys, liposome-encapsulated ami-

kacin prevented an increase of CFU counts (Fig. 4). At the
end of the 8-week period, the CFU in mice treated with
liposome-encapsulated amikacin were 1,000-fold lower than
those of untreated animals (P < 0.025),

whereas in mice

U.

given free amikacin i.v. the reduction in CFU was less than
10-fold

(Fig.

encapsulated

4 and Table

amikacin

are

1).

with liposome-

The results

similar to those for liver and

spleen; however, unlike those tissues, no difference in CFU
counts
i.m.

between

treatment

the

liposome-encapsulated-amikacin

groups

was

observed

at

2

weeks

in

and

4_

2

the

kidneys. At later times, the CFU counts in the i.m. treatment
group were reduced considerably (Table 1).

0

2

4

6

8

10

(v) Lymph nodes. In the lymph nodes, the results were
essentially the same as with the lungs, in that neither free nor
encapsulated amikacin was effective for 8 weeks (Fig. 5).
The i.m. treatment group, at a dose 60-fold higher than that
of the

free-

or

liposome-encapsulated-amikacin-treatment

Duration - Weeks
FIG. 5. Effects of free and liposome-encapsulated amikacin on
M. avium-M. intracellulare complex CFU counts in lymph nodes.
The symbols are defined in the legend to Fig. 1.

Downloaded from https://journals.asm.org/journal/aac on 23 July 2021 by 69.168.126.100.

ment. The symbols are given in the legend to Fig. 1.

1408

DCJZGCJNE5

ET AL.

ANTIMICROB. AGENTS CHEMOTHER.

7

w
3

6

Ii.

5
4

z
w
a

3
2

0

2

4

6

8

10

DURATION-WEEKS
FIG. 6. Effect of 10 mg of amikacin per kg encapsulated in unilamellar vesicles (*) or large, multilamellar vesicles (K) on the progression
of M. avium-M. intracellulare complex infection in the livers of beige mice. The drug was given by weekly i.v. injections for 5 weeks. The
effect of 5 mg of amikacin per kg in unilamellar vesicles was also determined in these experiments (O). Free amikacin was administered i.v.
at 10 mg/kg (O). The effect of injections of buffer (1) or empty liposomes (X) is also shown.

CFU in the lungs at the 4-week point but did not bring about
a significant reduction at later times (Fig. 8). Unilamellar
vesicles containing the same amount of amikacin (10 mg/kg)
also exhibited a slight CFU-reducing effect.
DISCUSSION
Our results demonstrate that i.v. delivery of amikacin
encapsulated in large, unilamellar liposomes arrests the
growth of M. avium-M. intracellulare complex organisms in
the livers and spleens of beige mice infected with M.
avium-M. intracellulare complex. Liposome-encapsulated
amikacin was substantially more effective than comparable
amounts of free amikacin administered i.v. This reduction
was achieved even with four or five weekly injections of 1/10
to 1/5 of the daily i.m. dose of 50 mg/kg. When the efficacies
of the liposome-encapsulated drug given i.v. and the free
drug given i.m. were expressed as reductions in CFU per
unit amount of drug, the former was severalfold higher than
the latter. These observations suggest that the negatively
charged liposomes used in our study were taken up by the
infected macrophages of the liver and spleen. It is also likely
that the liposomes, and hence the encapsulated amikacin,
were localized at intracellular sites where the mycobacteria
reside, since it is known that liposomes are avidly phagocytosed by macrophages in vitro and in vivo (6, 31, 32).
Although the duration of the treatment was 3 weeks, the
bacteriostatic effect of liposome-encapsulated amikacin persisted for at least 5 weeks, particularly in the liver and
kidneys. At the relatively low dose administered in liposomes, amikacin was not able to reduce the number of viable
M. avium-M. intracellulare organisms but did arrest the
growth of the organism. During the initial 2 weeks of
therapy, amikacin in liposomes was more effective in the
liver and spleen than a 60-fold higher total i.m. dose of free
amikacin. Liposome-encapsulated amikacin also stabilized
the number of viable mycobacteria in the kidneys at the
base-line level but did not inhibit replication of mycobacteria
in the lungs and lymph nodes. Our contention that increasing
the liposome size might influence the effectiveness of amikacin in the lungs was not borne out by the results of the
second series of experiments.

Downloaded from https://journals.asm.org/journal/aac on 23 July 2021 by 69.168.126.100.

values were 3.6-fold in the liver and 38-fold in the spleen.
Although the CFU counts in the i.m. group were reduced
below the base-line (day 1) levels over the 8-week period, the
reduction of CFU in the liver and spleen per unit drug dose
was still greater in the liposome-encapsulated-amikacin
treatment group than in the i.m. treatment group (2- and
6.3-fold, respectively).
Effects of increasing the dose of liposome-encapsulated
amikacin, prolonging the period of treatment, and increasing
the liposome size. In the second series of studies, we investigated the effects on M. avium-M. intracellulare complex
infection of (i) increasing the dose of amikacin from 5 to 10
mg/kg, (ii) increasing the number of injections from four to
five, i.e., at day 1 and at weekly intervals for up to 4 weeks,
and (iii) using large, multilamellar vesicles with the intention
of increasing lung localization (8). In view of the large
number of animals involved in testing the effects of the
above-described variables, the i.m. high dose of free amikacin was not examined in these experiments.
(i) Liver. Liposome-encapsulated amikacin administered
i.v. decreased the CFU counts from the values at day 1,
indicating the bactericidal effect of the treatment (Fig. 6).
Free amikacin (10 mg/kg) administered identically had no
effect on M. avium-M. intracellulare complex CFU counts.
At the 2-week point, all preparations produced similar decreases in CFU. At later time points, amikacin in large (2- to
3-,um-diameter), multilamellar vesicles was more effective
than the drug encapsulated in unilamellar vesicles (approximately 0.2 ,um in diameter in this series of experiments).
(ii) Spleen. Liposome-encapsulated amikacin given at a
dose of 5 mg/kg produced results comparable to those of
previous experiments (Fig. 7), except that the bacteriostatic
effect of the treatment was more pronounced in the second
series of experiments. Increasing the dose to 10 mg/kg was
slightly more effective. Administration of 10 mg of amikacin
per kg in large, multilamellar vesicles prolonged the bacteriostatic effect of the drug. Buffer-loaded liposomes or free
amikacin at the same dose had negligible effects on the
growth of the organism.
(iii) Lungs. The use of large, multilamellar vesicles to
deliver amikacin was marginally effective in reducing the
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FIG. 7. M. avium-M. intracellulare complex CFU counts in the spleens of beige mice treated with 10 mg of amikacin per kg in unilamellar
large, multilamellar vesicles administered i.v. in five weekly injections. The symbols are defined in the legend to Fig. 6.

In another experimental system, liposome-associated amphotericin B has also been shown to be effective against
Candida infection in the kidneys, as well as in the liver and
spleen (27). One of the advantages of administration of
liposome-encapsulated drugs is significant reduction of drug
toxicity. Administration of both amphotericin and adriamycin in liposomes substantially reduces drug toxicity in patients (12, 26).
Encapsulation in liposomes enhances the antimicrobial
activities of a number of antibiotics against infections both in
cultured cells and in vivo (for reviews, see references 11 and
30). Vladimirsky and Ladigina (35) have shown that administration of streptomycin in liposomes to mice infected with
M. tuberculosis causes a significant reduction of colony
counts in the spleen and increases survival compared with
the free drug. Orozco et al. (29) have also found an enhanced

effect of liposome-encapsulated rifampin and isoniazid on
reduction of M. tuberculosis CFU in the spleen. However,
survival was not prolonged in mice that received encapsulated drugs. These two studies used liposomes of different
composition and prepared by different methods.
Although the results obtained in this study are encouraging for the use of liposomes in the therapy of M. avium-M.
intracellulare complex infections, further work is necessary
to optimize the targeting of amikacin and other antimycobacterial agents to sites of M. avium-M. intracellulare complex infection in vivo. Future experiments will attempt to
increase the localization of amikacin in the lungs by aerosol
administration (8) and in the lymph nodes by subcutaneous
injection (24) or antibody targeting of liposomes (7). It
should also be possible to reduce the CFU counts below the
initial levels by administering a higher dose of liposome-
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FIG. 8. Effect of 10 mg of amikacin per kg in unilamellar or large, multilamellar liposomes on M. avium-M. intracellulare complex CFU
counts in the lungs. The symbols and experimental details are given in the legend to Fig. 6.
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encapsulated amikacin, since the amount of lipid injected in
our experiments was well below the tolerable limit. It may
also be possible to develop therapy using both free and
liposome-encapsulated drugs or combination chemotherapy.
When more effective treatment regimens are developed, it
will be necessary to test their effects on other more drugresistant M. avium-M. intracellulare complex strains. Previous experience with the use of liposomal amphotericin B in
the treatment of patients with candidiasis (26) and the use of
liposome-encapsulated doxorubicin in phase I trials (12) is
expected to expedite the application of effective liposomebased therapy regimens in mice to the treatment of patients
with M. avium-M. intracellulare complex infections.
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